IGL Group has acquired Celsior®
The IGL Group, based in France, has acquired Celsior® from Sanofi Genzyme for US$11.5 million.
Companies within the IGL Group develop research programmes that have led to the development of products designed specifically to improve organ recovery, preservation, transport and evaluation systems before transplant. The IGL-1® preservation solution is particularly well suited for expanded criteria donors.
Celsior®, producing liquid compositions for perfusion, reperfusion and preservations of organs, is part of the Sanofi Genzyme group, a global healthcare leader focused on the research, development, manufacturing and marketing of innovative therapeutic solutions.
Sanofi Genzyme is engaged in the research, development, manufacturing and marketing of innovative therapeutic solutions. Sanofi's core strength is in the healthcare sector, with seven growth platforms: diabetes solutions, human vaccines, innovative drugs, consumer healthcare, emerging markets, animal health and the new Genzyme.
Oaklins' team in France advised the buyer in this transaction.
Talk to the deal team
Thibaut de Monclin
A group of Chilean investors has acquired Farmacias Ahumada
A group of Chilean investors has acquired Farmacias Ahumada S.A. from Walgreens Boots Alliance.Learn more
Shield Therapeutics has completed a fundraising
Shield Therapeutics plc has raised funds to bolster the expansion of ACCRUFeR®, the sole FDA-approved therapy for iron deficiency and to drive the business. Additionally, it positions the company for further investments.Learn more
Haydale Graphene Industries has completed a fundraising
Haydale Graphene Industries PLC has raised funds to continue to develop the ongoing commercialization of its proprietary HDPlas® plasma functionalization process.Learn more